Literature DB >> 19956845

Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma.

Kazumoto Murata1, Hideto Suzuki, Hiroshi Okano, Takashi Oyamada, Yoshikazu Yasuda, Atsushi Sakamoto.   

Abstract

Des-gamma-carboxy prothrombin (DCP) is an established HCC tumor marker, but the precise mechanism of its production is still unclear. Recently, we demonstrated that cytoskeletal changes during epithelial-to-fibroblastoid conversion (EFC) or epithelial mesenchymal transition (EMT) induced by chemicals plays a critical mechanistic role in DCP production via impairment in vitamin K uptake. Our proposed mechanism of DCP production is consistent with substantial clinical evidence. Supplementary vitamin K2 analogues reduced serum DCP levels in hepatocellular carcinoma (HCC) patients. HCC patients with high serum DCP are associated with vascular invasion, metastasis and tumor recurrence. On the other hand, hypoxia has been reported to induce EMT or cytoskeletal changes. Therefore, we examined whether hypoxia induced DCP production during EFC or EMT in HCC cells. Indeed, hypoxic stimulation induced hepatoma cell lines (HepG2 or PLC/PRF/5 cells) to undergo EFC or EMT and these cells produced DCP. Immunofluorescence study demonstrated that hypoxic stimulation impaired labeled low-density lipoprotein uptake, which was a surrogate for vitamin K uptake. In addition, fine filamentous actin network, which has crucial role for clathrin-mediated endocytosis of vitamin K, was disrupted in DCP producing cells by hypoxic stimulation. Thus, hypoxic stimulation induced HCC cells to produce DCP in the same mechanism as chemicals. Furthermore, immunohistochemical study using surgically resected HCC samples showed that a positive staining of nuclear hypoxia inducible factor (HIF)-1alpha was more frequently observed in HCC cells with stronger staining intensity of DCP. Importantly, clinical observations that DCP as an HCC tumor marker was more useful in larger tumors, which is likely to be exposed with hypoxia during tumor development, support our results.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19956845

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  23 in total

1.  Epithelial-mesenchymal transitions and hepatocarcinogenesis.

Authors:  Janice Jou; Anna Mae Diehl
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

Review 2.  Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.

Authors:  Masatoshi Kudo
Journal:  Int J Clin Oncol       Date:  2010-05-28       Impact factor: 3.402

3.  A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment.

Authors:  Masaya Saito; Yasushi Seo; Yoshihiko Yano; Akira Miki; Masaru Yoshida; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2012-03-24       Impact factor: 7.527

Review 4.  Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.

Authors:  Hao Xing; Cunling Yan; Liming Cheng; Nianyue Wang; Shuyang Dai; Jianyong Yuan; Wenfeng Lu; Zhouchong Wang; Jun Han; Yijie Zheng; Tian Yang
Journal:  Tumour Biol       Date:  2016-10-13

5.  Association of des-γ-carboxy prothrombin production and Sonazoid-enhanced ultrasound findings in hepatocellular carcinomas of different histologic grades.

Authors:  Kazumoto Murata; Akiko Saito; Satoshi Katagiri; Shunichi Ariizumi; Masayuki Nakano; Masakazu Yamamoto
Journal:  J Med Ultrason (2001)       Date:  2017-08-21       Impact factor: 1.314

6.  Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma.

Authors:  Hideto Suzuki; Kazumoto Murata; Takaya Gotoh; Masao Kusano; Hiroshi Okano; Takashi Oyamada; Yoshikazu Yasuda; Masatoshi Imamura; Masatoshi Kudo; Masashi Mizokami; Atsushi Sakamoto
Journal:  J Gastroenterol       Date:  2011-07-09       Impact factor: 7.527

7.  Upregulation of des-gamma-carboxy-prothrombin after portal vein embolization in a cirrhotic patient with hepatocellular carcinoma.

Authors:  Tetsuro Sohda; Kaoru Iwata; Akira Anan; Hideo Kunimoto; Kaoru Yotsumoto; Keiji Yokoyama; Daisuke Morihara; Yasuaki Takeyama; Satoshi Shakado; Akinobu Osame; Shinichi Kora; Jun Ohishi; Yasushi Yamauchi; Tomoaki Noritomi; Kengo Yoshimitsu; Yuichi Yamashita; Shotaro Sakisaka
Journal:  Clin J Gastroenterol       Date:  2015-09-15

8.  Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma.

Authors:  Junichi Shindoh; Yusuke Kawamura; Yuta Kobayashi; Masahiro Kobayashi; Norio Akuta; Satoshi Okubo; Yoshiyuki Suzuki; Masaji Hashimoto
Journal:  Ann Surg Oncol       Date:  2021-04-26       Impact factor: 5.344

9.  Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.

Authors:  Sojung Han; Hye Jin Choi; Seung-Hoon Beom; Hye Rim Kim; Hyein Lee; Jae Seung Lee; Hye Won Lee; Jun Yong Park; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Jinsil Seong; Jong Yun Won; Beom Kyung Kim
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-23       Impact factor: 4.553

Review 10.  Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets.

Authors:  Tamara Severi; Hannah van Malenstein; Chris Verslype; Jos F van Pelt
Journal:  Acta Pharmacol Sin       Date:  2010-10-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.